Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07339722 | A Study of LY4515100 in Healthy Participants | PHASE1 | RECRUITING | 40 | — | — | Jan 15, 2026 | Jul 1, 2026 | Mar 2, 2026 | 1 | United States |
SAEs of LY4515100
| Arm | Type | Description |
|---|---|---|
| LY4515100 of Part A (SAD) | EXPERIMENTAL | Single-ascending doses of LY4515100 will be given orally |
| LY4515100 of Part B (MAD) | EXPERIMENTAL | Multiple-ascending doses of LY4515100 will be given orally |
| Placebo Part A | PLACEBO_COMPARATOR | Placebo will be given orally |
| Placebo Part B | PLACEBO_COMPARATOR | Placebo will be given orally |
| Name | Type | Description |
|---|---|---|
| LY4515100 via SAD | DRUG | given orally |
| LY4515100 via MAD | DRUG | given orally |
Inclusion Criteria: * Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and cardiac monitoring. * Have a body mass index within the range of 18.5 to 32.0 kilograms per square meter (kg/m\^2) (inclusive). * Individ...